Is TSLA a buy, hold, or sell?
TSLA carries a valuation grade of Avoid. The trailing P/E of 343.8 sits 1222% above the Consumer Cyclical sector median of 26.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $97–$459 — implying a -27% margin of safety at the current price of $381.59. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 6% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 17.1% earnings surprise. Analyst estimate revisions are trending upward.
What are TSLA's key risk factors?
With a beta of 1.80, TSLA exhibits a highly aggressive risk profile relative to the broad market. The 95th-percentile CVaR of -13.6% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.4% of total portfolio loss in the worst 5% of months. Net margins of 3.9% fall below the Consumer Cyclical sector average of 10%, suggesting margin pressure. The balance sheet is conservatively leveraged at 19% debt-to-equity.
Implied volatility of 2.2% is below realized volatility of 47.2%, potentially making options relatively cheap. Insider transactions show net buying of $269.1M over the trailing period, a signal often associated with management confidence. Short interest is low at 2.3% of float, suggesting limited bearish conviction.
How does TSLA fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — TSLA carries a beta of 1.80, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, TSLA shows the strongest co-movement with RIVN (0.32), XPEV (0.27), LI (0.27). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The TSLA analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning TSLA’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
